Cantor Fitzgerald Forecasts Novavax FY2025 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Novavax in a report released on Friday, October 24th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the biopharmaceutical company will post earnings of $2.23 per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $18.00 price objective on the stock. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share.

NVAX has been the topic of several other research reports. HC Wainwright boosted their price objective on Novavax from $10.00 to $11.00 and gave the company a “buy” rating in a report on Thursday. Bank of America reiterated an “underperform” rating and issued a $7.00 price objective (down previously from $9.00) on shares of Novavax in a report on Wednesday, August 20th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Novavax in a report on Saturday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $11.33.

Novavax Price Performance

NASDAQ:NVAX opened at $8.52 on Monday. Novavax has a 52 week low of $5.01 and a 52 week high of $11.55. The company has a quick ratio of 2.34, a current ratio of 2.36 and a debt-to-equity ratio of 5.93. The company has a market capitalization of $1.38 billion, a P/E ratio of 3.74, a P/E/G ratio of 0.13 and a beta of 2.74. The stock’s fifty day moving average is $8.40 and its two-hundred day moving average is $7.44.

Novavax (NASDAQ:NVAX) last posted its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.69. Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.The company had revenue of $239.24 million for the quarter, compared to the consensus estimate of $149.19 million. During the same quarter in the previous year, the business earned $0.99 earnings per share. The company’s revenue for the quarter was down 42.4% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bayforest Capital Ltd acquired a new position in Novavax during the 1st quarter worth $404,000. Kingstone Capital Partners Texas LLC acquired a new position in shares of Novavax during the 2nd quarter worth about $1,016,000. Park West Asset Management LLC acquired a new position in shares of Novavax during the 1st quarter worth about $16,210,000. Shah Capital Management boosted its position in shares of Novavax by 3.4% during the 2nd quarter. Shah Capital Management now owns 11,511,780 shares of the biopharmaceutical company’s stock worth $72,524,000 after acquiring an additional 379,934 shares in the last quarter. Finally, Entropy Technologies LP acquired a new position in shares of Novavax during the 1st quarter worth about $191,000. 53.04% of the stock is owned by institutional investors and hedge funds.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.